Zobrazeno 1 - 10
of 45
pro vyhledávání: '"MARK GOLDIN"'
Autor:
Mark Goldin, Kolton Smith, Ioannis Koulas, Tungming Leung, Mayuri Ravi, Sanjit Parhar, Sejal Shah, Kayla Floyd, Lori Ohanesian, Rachel Bain, Daniella Defonte, Kanta Ochani, Amanda Lin, Bhumi Patel, Nikolaos Tsaftaridis, Jack Jnani, Alex C. Spyropoulos
Publikováno v:
TH Open, Vol 08, Iss 02, Pp e209-e215 (2024)
Background Andexanet is U.S. Food and Drug Administration (FDA) approved for the reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes.
Externí odkaz:
https://doaj.org/article/b4c8d7cd0de345d594f879f98c252755
Autor:
Alex C. Spyropoulos, Mark Goldin, Walter Ageno, Gregory W. Albers, C. Gregory Elliott, William R. Hiatt, Jonathan L. Halperin, Gregory Maynard, P. Gabriel Steg, Jeffrey I. Weitz, Theodore E. Spiro, Wentao Lu, Jessica Marsigliano, Gary E. Raskob, Elliot S. Barnathan
Publikováno v:
TH Open, Vol 06, Iss 03, Pp e177-e183 (2022)
Background The MARINER trial evaluated whether postdischarge thromboprophylaxis with rivaroxaban could reduce the primary outcome of symptomatic venous thromboembolism (VTE) or VTE-related death in acutely ill medical patients at risk for VTE. Althou
Externí odkaz:
https://doaj.org/article/8d224873bb1841ca8d9854b241be5ec7
Autor:
Alex C. Spyropoulos, Stuart L. Cohen, Eugenia Gianos, Nina Kohn, Dimitrios Giannis, Saurav Chatterjee, Mark Goldin, Marty Lesser, Kevin Coppa, Jamie S. Hirsch, Thomas McGinn, Matthew A. Barish, the COVID‐19 Consortium Group
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 2, Pp 296-300 (2021)
Abstract Background Antithrombotic guidance statements for hospitalized patients with coronavirus disease 2019 (COVID‐19) suggest a universal thromboprophylactic strategy with potential to escalate doses in high‐risk patients. To date, no clear a
Externí odkaz:
https://doaj.org/article/b8af46e3348d4332bacdae4b6325cabf
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 5, Pp n/a-n/a (2021)
Externí odkaz:
https://doaj.org/article/3285a216bd464ab2871ecc9024a6a89c
Autor:
MOGELY KHUBUTIYA, BORIS GRAFOV, MIKHAIL GOLDIN, ALEXEI DAVYDOV, VLADIMIR KOLESNIKOV, MARK GOLDIN
Publikováno v:
Journal of Electrochemical Science and Engineering, Vol 1, Iss 1, Pp 27-37 (2011)
The number of medical applications of electrochemistry has grown in recent years due to the increased applications of electrochemical concepts to various systems of the organism. This includes electrochemically controlled hemosorption detoxification,
Externí odkaz:
https://doaj.org/article/c9577b0f5ce245ff8308875e448c0117
Publikováno v:
British Journal of Hospital Medicine. 84:1-11
Hospitalised patients with coronavirus disease 2019 (COVID-19) are at a significantly higher risk of having thromboembolic events while in hospital and in the immediate post-hospital discharge period. Based on early data from observational studies, m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77c2626e4096ea60285315f79a4ac90d
https://doi.org/10.12968/hmed.2022.0519
https://doi.org/10.12968/hmed.2022.0519
Autor:
Alex C. Spyropoulos, Jean M. Connors, James D. Douketis, Mark Goldin, Beverley J. Hunt, Taiwo R. Kotila, Renato D. Lopes, Sam Schulman, null the International Society on Thrombosis and Haemostasis
Publikováno v:
Journal of Thrombosis and Haemostasis. 20:2226-2236
Despite the emergence of high quality randomized trial data with the use of antithrombotic agents to reduce the risk of thromboembolism, end-organ failure, and possibly mortality in patients with coronavirus disease 2019 (COVID-19), questions still r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38991d17009b9ba7cf8b3b06baa46304
https://doi.org/10.1111/jth.15809
https://doi.org/10.1111/jth.15809
Autor:
Panagiota Gianni, Mark Goldin, Sam Ngu, Stefanos Zafeiropoulos, Georgios Geropoulos, Dimitrios Giannis
Publikováno v:
World Journal of Experimental Medicine. 12:53-67
Coronavirus disease 2019 (COVID-19) causes acute microvascular thrombosis in both venous and arterial structures which is highly associated with increased mortality. The mechanisms leading to thromboembolism are still under investigation. Current evi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d890a7640934129f46688b79eefe19dc
https://doi.org/10.5493/wjem.v12.i4.53
https://doi.org/10.5493/wjem.v12.i4.53
Autor:
Dimitrios Giannis, Mark Goldin, Husneara Rahman, Cristina P Sison, Martin Lesser, Sam Ngu, James Tsang, Michael Qiu, Shreya Sanghani, Jackson Yeh, Miltiadis Matsagkas, Eleni Arnaoutoglou, Alex C. Spyropoulos
Publikováno v:
Thrombosis and Haemostasis.
Background Coronavirus disease 2019 (COVID-19) is associated with venous and arterial thromboembolism (VTE and ATE) and all-cause mortality (ACM) in hospitalized patients. High-quality data are needed on post-discharge outcomes in patients with cardi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e25351eb24efeb6302553be5ba3eeab9
https://doi.org/10.1055/a-2087-3003
https://doi.org/10.1055/a-2087-3003
Publikováno v:
American Journal of Therapeutics. 29:e425-e436
Coronavirus disease 2019 (COVID-19) is associated with elevated rates of major and fatal thrombotic events, postulated to be the result of a hypercoagulable state mediated through inflammatory and immunomodulatory mechanisms. Early observational stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::632900b9d6eb9c3ce21c5e33710ea3bf
https://doi.org/10.1097/mjt.0000000000001515
https://doi.org/10.1097/mjt.0000000000001515